Nerve-stimulating wearable targets heavy menstrual bleeding

Spark Biomedical has introduced OhmBody, a neurostimulation wearable designed to reduce heavy menstrual bleeding without drugs or hormones, debuting at CES 2026. Building on the company's prior FDA-cleared device for opioid withdrawal, OhmBody uses transcutaneous auricular neurostimulation to stimulate the vagus and trigeminal nerves around the ear. This nerve stimulation regulates the nervous system and influences blood flow by activating platelets in the spleen, thereby reducing menstrual blood loss. A recent peer-reviewed pilot study with 16 participants, including women with von Willebrand Disease and unexplained heavy bleeding, showed that daily use of OhmBody during menstruation reduced blood loss by over 50% and shortened periods by nearly 20%, alongside improvements in cramping, fatigue, and quality of life. Currently positioned as a non-invasive, hormone-free wellness device, OhmBody is not yet FDA-cleared but is moving toward medical approval, with further clinical trials planned. Spark Biomedical emphasizes the device’s